Valeant Pharmaceuticals International

United States of America

Back to Profile

1-18 of 18 for Valeant Pharmaceuticals International Sort by
Query
Excluding Subsidiaries
Aggregations Reset Report
IP Type
        Patent 11
        Trademark 7
Jurisdiction
        World 10
        United States 4
        Europe 4
IPC Class
A61K 31/425 - Thiazoles 2
A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials 2
A61L 15/60 - Liquid-swellable gel-forming materials, e.g. super-absorbents 2
C07D 275/03 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms 2
C08L 83/04 - Polysiloxanes 2
See more
NICE Class
05 - Pharmaceutical, veterinary and sanitary products 6
42 - Scientific, technological and industrial services, research and design 2
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations 1

1.

VALEANT

      
Application Number 014392831
Status Registered
Filing Date 2015-07-22
Registration Date 2015-11-04
Owner Valeant Pharmaceuticals International (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

food supplements.

2.

Silicone gel-based compositions for wound healing and scar reduction

      
Application Number 14031303
Grant Number 08859618
Status In Force
Filing Date 2013-09-19
First Publication Date 2014-01-23
Grant Date 2014-10-14
Owner Valeant Pharmaceuticals International (USA)
Inventor
  • Palefsky, Irwin
  • Wilson, Ni'Kita

Abstract

This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing.

IPC Classes  ?

  • A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
  • A61K 31/695 - Silicon compounds
  • A61K 31/74 - Synthetic polymeric materials
  • A61K 8/89 - Polysiloxanes
  • A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
  • A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
  • C08L 83/04 - Polysiloxanes
  • A61L 15/60 - Liquid-swellable gel-forming materials, e.g. super-absorbents
  • C08G 77/00 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon
  • C08G 77/46 - Block- or graft-polymers containing polysiloxane sequences containing polyether sequences
  • C08G 77/50 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms by carbon linkages

3.

DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANIILIDES AS POTASSIUM CHANNEL MODULATORS

      
Application Number US2011022345
Publication Number 2011/094186
Status In Force
Filing Date 2011-01-25
Publication Date 2011-08-04
Owner VALEANT PHARMACEUTICALS INTERNATIONAL (USA)
Inventor
  • Vernier, Jean-Michel
  • Delarosa, Martha
  • Chen, Huanming
  • Wu, Jim, Zhen
  • Larson, Gary, Lee
  • Cheney, Lan, Wayne

Abstract

This invention provides a compound of formula IA where X = 0 or S; Y is 0 or S; q = 1 or 0; and other substituents are defined herein. Such compounds can affect the opening of, or otherwise modulate, voltage-gated potassium channels. Such compounds useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.

IPC Classes  ?

  • A01N 37/36 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids

4.

MODIFIED RELEASE FORMULATION AND METHODS OF USE

      
Application Number US2011021498
Publication Number 2011/090923
Status In Force
Filing Date 2011-01-18
Publication Date 2011-07-28
Owner VALEANT PHARMACEUTICALS INTERNATIONAL (USA)
Inventor Nadjsombati, Biljana

Abstract

A modified release pharmaceutical formulation includes about 30-70% N-(2-amino-4- (fluorobenzylamino)-phenyl) carbamic acid ethyl ester (retigabine), or a pharmaceutically acceptable salt, solvate or hydrate thereof, about 5-30% of a drug delivery matrix including hydroxypropylmethylcellulose (HPMC), and an enteric polymer. The pharmaceutical formulation produces a sustained plasma concentration of retigabine following administration to a subject for 4- 20 hours longer than the time required for in vitro release of 80% of retigabine. The plasma concentration vs. time profile of this formulation is substantially flat over an extended period lasting for about 4 hours to about 36 hours. A method of treating a disorder characterized by nervous system hyperexcitability includes administering to a subject an effective amount of these pharmaceutical formulations.

IPC Classes  ?

  • A01N 47/06 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom containing —O—CO—O— groupsThio-analogues thereof
  • A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid

5.

BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS

      
Application Number US2009048504
Publication Number 2010/008894
Status In Force
Filing Date 2009-06-24
Publication Date 2010-01-21
Owner VALEANT PHARMACEUTICALS INTERNATIONAL (USA)
Inventor
  • Wu, Jim, Zhen
  • Vernier, Jean-Michel
  • Chen, Huanming
  • Song, Jianlan

Abstract

The present invention relates to benzyloxyanilide derivatives having the following structural formula (I): The compounds of the present invention are useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.

IPC Classes  ?

6.

MODIFIED RELEASE FORMULATION AND METHODS OF USE

      
Application Number US2009051052
Publication Number 2010/009433
Status In Force
Filing Date 2009-07-17
Publication Date 2010-01-21
Owner VALEANT PHARMACEUTICALS INTERNATIONAL (USA)
Inventor Nadjsombati, Biljana

Abstract

A modified release pharmaceutical formulation includes about 30-70% N-(2-amino-4- (fluorobenzylamino) -phenyl) carbamic acid ethyl ester (retigabine), or a pharmaceutically acceptable salt, solvate or hydrate thereof, about 5-30% of a drug delivery matrix including hydroxypropylmethylcellulose (HPMC), about 1.0-10% of an anionic surfactant, and an enteric polymer. The pharmaceutical formulation produces a sustained plasma concentration of retigabine following administration to a subject for 4-20 hours longer than the time required for in vitro release of 80% of retigabine. A formulation includes about 30-70% N-(2-amino-4- (fluorobenzylamino) -phenyl) carbamic acid ethyl ester (retigabine), or a pharmaceutically acceptable salt, solvate or hydrate thereof, about 5-30% of a drug delivery matrix, and an agent for retarding release in the gastric environment. The plasma concentration vs. time profile of this formulation is substantially flat over an extended period lasting for about 4 hours to about 36 hours. A method of treating a disorder characterized by nervous system hyperexcitability includes administering to a subject an effective amount of these pharmaceutical formulations.

IPC Classes  ?

  • A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof

7.

SILICONE GEL-BASED COMPOSITIONS FOR WOUND HEALING AND SCAR REDUCTION

      
Application Number US2008078340
Publication Number 2009/046033
Status In Force
Filing Date 2008-09-30
Publication Date 2009-04-09
Owner
  • VALEANT PHARMACEUTICALS INTERNATIONAL (USA)
  • MEDA AB (Sweden)
Inventor
  • Palefsky, Irwin
  • Wilson, Ni'Kita

Abstract

This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing.

IPC Classes  ?

  • A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
  • A61L 15/60 - Liquid-swellable gel-forming materials, e.g. super-absorbents
  • C08L 83/04 - Polysiloxanes

8.

DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS

      
Application Number US2008066984
Publication Number 2008/157404
Status In Force
Filing Date 2008-06-13
Publication Date 2008-12-24
Owner VALEANT PHARMACEUTICALS INTERNATIONAL (USA)
Inventor
  • Vernier, Jean-Michel
  • Ouk, Samedy
  • De La Rosa, Martha, Alicia

Abstract

This invention provides potassium channel modulators which are compounds of formula (I), (formula I), where at least one of W and Z is N; where the moiety (formula II), is one of Groups A or B below (formula A), where Ar is a 1,2-fused, six membered ring aromatic group, bearing substituents R1 and R2 as defined below, and containing zero or one ring nitrogen atom; and where other substituents are defined herein. The invention also provides a composition comprising a pharmaceutically acceptable carrier and at least one of the following: i) a pharmaceutically effective amount of a compound of formula I and ii) a pharmaceutically acceptable salt, ester, or prodrug thereof. The invention also provides a method of preventing or treating a disease or disorder which is affected by activities of potassium channels, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I or a salt, ester, or prodrug thereof.

IPC Classes  ?

  • C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
  • C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 471/04 - Ortho-condensed systems
  • A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
  • A61P 25/08 - AntiepilepticsAnticonvulsants

9.

3-HYDROXYISOTHIAZOLE-4-CARBOXAMIDINE DERIVATIVES AS CHK2 INHIBITORS

      
Application Number US2008067763
Publication Number 2008/157802
Status In Force
Filing Date 2008-06-20
Publication Date 2008-12-24
Owner VALEANT PHARMACEUTICALS INTERNATIONAL (USA)
Inventor
  • Wu, Jim, Zhen
  • Chen, Huanming

Abstract

This invention provides compounds of Formula (I), which are inhibitors of Chk2 and are useful as a radiation protection agents in anticancer radiotherapy. A method of modulating Chk2 in vitro includes treating a substrate with Chk2 in the presence of compounds of formula I. A method of making a compound of formula I includes: a) forming a biaryl amine having an amino (NH2) group; b) converting the amino group to an isothiocyanate group; c) adding a cyanoacetamide to said isothiocyanate group to form a thioamide adduct; d) cyclizing said thioamide adduct to form an isothiazole having a cyano group; and e) adding an amine to said cyano group to form a carboxamidine group.

IPC Classes  ?

  • C07D 275/03 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • A61K 31/425 - Thiazoles
  • A61P 39/00 - General protective or antinoxious agents

10.

1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS

      
Application Number US2007024607
Publication Number 2008/066900
Status In Force
Filing Date 2007-11-28
Publication Date 2008-06-05
Owner VALEANT PHARMACEUTICALS INTERNATIONAL (USA)
Inventor
  • Chen, Huanming
  • Song, Jenny
  • Vernier, Jean-Michel
  • Wu, Jim, Zhen

Abstract

This invention is directed to compounds of formula (I), where G is -O-, -S-, -C(g1)(g2)-, or -NH-, and n = 1, 2, or 3. Such compounds modulate potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders which are affected by modulation of potassium ion channels. One such condition is seizure disorders.

IPC Classes  ?

  • C07C 233/41 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
  • C07C 271/30 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide

11.

DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS

      
Application Number US2007018571
Publication Number 2008/024398
Status In Force
Filing Date 2007-08-22
Publication Date 2008-02-28
Owner VALEANT PHARMACEUTICALS INTERNATIONAL (USA)
Inventor
  • Vernier, Jean-Michel
  • De La Rosa, Martha, Alicia
  • Chen, Huanming
  • Wu, Jim, Zhen
  • Larson, Gary, Lee
  • Cheney, Ian, Wayne

Abstract

This invention provides a compound of formula (IA) where X = O or S; Y is O or S; q = 1 or 0; and other substituents are defined herein. Such compounds can affect the opening of, or otherwise modulate, voltage-gated potassium channels. They are potentially useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.

IPC Classes  ?

12.

PHENYLAMINO ISOTHIAZOLE CARBOXAMIDINES AS MEK INHIBITORS

      
Application Number US2006022491
Publication Number 2006/133417
Status In Force
Filing Date 2006-06-07
Publication Date 2006-12-14
Owner VALEANT PHARMACEUTICALS INTERNATIONAL (USA)
Inventor
  • Abdellaoui, Hassan, El
  • Tam, Robert
  • Chamakura, Varaprasad
  • Lang, Stanley
  • Hong, Zhi
  • Barawkar, Dinesh
  • Maderna, Andreas

Abstract

The invention concerns compounds of formula (I) which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted- 3-hydroxy-5- arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)- ones.

IPC Classes  ?

  • C07D 275/03 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • A61K 31/425 - Thiazoles
  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61P 35/00 - Antineoplastic agents

13.

Miscellaneous Design

      
Application Number 004239455
Status Registered
Filing Date 2005-01-13
Registration Date 2006-01-27
Owner Valeant Pharmaceuticals International (USA)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

House mark for a full line of pharmaceutical preparations and dermatological products. Research and development services in the field of pharmaceuticals.

14.

V

      
Serial Number 78454524
Status Registered
Filing Date 2004-07-21
Registration Date 2006-09-12
Owner Valeant Pharmaceuticals International ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

house mark for a full line of pharmaceutical preparations and dermatological pharmaceutical products

15.

V

      
Serial Number 78454558
Status Registered
Filing Date 2004-07-21
Registration Date 2007-04-10
Owner Valeant Pharmaceuticals International ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

house mark for a full line of pharmaceutical preparations and dermatological products

16.

VALEANT

      
Application Number 003726809
Status Registered
Filing Date 2004-03-24
Registration Date 2007-09-20
Owner Valeant Pharmaceuticals International (USA)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

A full line of pharmaceutical preparations and dermatological products. Research and development services in the field of pharmaceuticals, except clinical research services.

17.

VALEANT

      
Serial Number 78308411
Status Registered
Filing Date 2003-10-02
Registration Date 2008-05-27
Owner VALEANT PHARMACEUTICALS INTERNATIONAL ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

House mark for a full line of pharmaceutical preparations and dermatological products for humans

18.

KINERASE

      
Application Number 001304161
Status Registered
Filing Date 1999-09-09
Registration Date 2001-10-08
Owner Valeant Pharmaceuticals International (USA)
NICE Classes  ? 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations

Goods & Services

Cosmetics, skin cream and lotion, body cream and lotion, and facial cream and lotion.